The Conjugate Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Conjugate Vaccine Market:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
According to The Business Research Company’s Conjugate Vaccine Global Market Report 2024, The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends..
The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity..
The increase in the use of conjugate vaccines for adults is expected to propel the growth of the conjugate vaccine market. Conjugate vaccines are designed to stimulate a strong immune response against bacterial capsular polysaccharides, enhancing the body's defense mechanism against bacterial infections. The use of conjugate vaccines in adults helps reduce the risk of severe illness, complications, and transmission of these bacterial diseases by stimulating a robust immune response. For instance, according to the Historical national influenza vaccination coverage 2020-2022, published by the National Centre for Immunization Research and Surveillance, an Australia-based research organization, historical influenza vaccine coverage at the end of 2022 by 15 - < 50 years age group was 29.5%, an increase from 22.8% recorded in 2021. Therefore, the increase in the use of conjugate vaccines for adults is driving the growth of the conjugate vaccine market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Innovation in conjugate vaccines is a key trend gaining popularity in the conjugate vaccine market. Companies operating in the conjugate vaccine market are focused on developing innovative conjugate vaccines to sustain their position in the market. For instance, in June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes already covered by PREVNAR 13 and conjugates for seven additional serotypes associated with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.
The conjugate vaccine market report table of contents includes:
1. Executive Summary
2. Conjugate VaccineMarket Characteristics
3.Conjugate Vaccine Market Trends And Strategies
4. Conjugate VaccineImpact Of Market analysis
5. Conjugate VaccineMarket Size And Growth
6.Conjugate Vaccine Segmentation
7. Conjugate VaccineRegional And Country Analysis
.
.
.
27. Conjugate VaccineCompetitive Landscape And Company Profiles
28.Conjugate Vaccine Key Mergers And Acquisitions
29. Conjugate VaccineFuture Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Sanofi S.A.
- Pfizer Inc. Merck & Co. Inc.
- GlaxoSmithKline PLC
- Bharat Biotech International Limited
- Serum Institute of India Private Limited
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Global Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), By Indication (Influenza, Pneumococcal, Meningococcal, And Others) By End Users (Pediatrics And Adults) - Global Forecast Till 2027SegmentationThe global conjugate vaccine is segmented on the basis of type, indication, and end users.
On the basis of end users, it is segmented into pediatrics and adults.Get Sample Report at https://www.marketresearchfuture.com/sample_request/4387Market HighlightsConjugates vaccines are formed by covalently bonding a weak antigen to the strong antigen, it boosts the hosts’ immune response.
Vaccines are given to children to prevent transmission of diseases through infections and seasonal variation.
Young children are more susceptible to infection that drives growth of the market.
Moreover, increasing government support is expected to fuel the market’s growth during the forecast period.
The effectiveness of vaccine conjugates and need more advanced research, which may hinder the growth of the market during the forecasted period.The Global Conjugate Vaccine Market is expected to grow at a CAGR of 10.5% during the forecast period 2017-2027.Taste the market data and market information presented through more than 105 market data tables and figures spread over 115 pages of the project report.
Vaccine Conjugate Market Growing Demand for Disease Eradication in Global OpportunitiesThe report studies the global Vaccine Conjugate Market’s historical growth trajectory in order to provide pointers as to the major drivers and restraints affecting the market’s growth prospects and derive market growth markers that can indicate the market’s future growth trajectory over the forecast period from 2017 to 2023.The global Vaccine Conjugate Market is expected to exhibit a robust 10.5% CAGR over the forecast period, according to MRFR.Conjugate vaccines are vaccines containing two antigens, one strong and one weak.
The stronger antigen is generally made from proteins and is attached to a weaker polysaccharide antigen to form conjugate vaccines.Competitive Analysis:Leading players in the global Vaccine Conjugate Market include,GSK plcFablifeSanofi Pasteur SASinovac Biotech Ltd.GreenSignal Bio Pharma LimitedBavarian NordicTaj Pharmaceuticals LimitedIDT BiologicsPfizerSutroVax Inc.and Merck & Co. Inc.Avail Free Sample@ https://www.marketresearchfuture.com/sample_request/4387Conjugate vaccines are used to counter diseases whose associated pathogens do not elicit a significant response from the human immune system on their own.
As a result, a stronger antigen is attached to the weaker pathogen to make it more prominent and to elicit a stronger response from the immune system.
The first conjugate vaccine was developed in response to the outbreak of meningitis, which still remains among the top targeted diseases in the Vaccine Conjugate Market.The growing government support for mass-scale vaccinations for disease eradication is likely to remain the prime driver for the global Vaccine Conjugate Market over the forecast period.
Vaccination has taken on a key role in eliminating diseases such as meningitis, which can become a serious health problem given the right conditions.
The growing support for further advancement in vaccine research and development is also likely to be a major driver for the global Vaccine Conjugate Market over the forecast period.
The Pneumococcal Conjugate Vaccine Market 2021 research report gives emerging industry data, global segments and regional outlook.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the pneumococcal conjugate vaccine market include Glaxosmithkline plc, LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Pneumococcal Conjugate Vaccine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/pneumococcal-conjugate-vaccine-market/download-sampleMarket DynamicsPneumococcal disease, one of the leading vaccine-preventable disorders, and one of the major causes of young children’s mortality rate worldwide is the key trend driving this market’s growth.
The demand for this vaccine is on the rise since it effectively prevents antibiotic-resistant pneumococcal infections caused by vaccine serotypes and the spread of the bacteria in the community.
